Table 3 Percentage of patients with pneumonia in recent studies investigating ICS/LABA combinations versus LABA monotherapy in COPD patients
Study reference | Drugs and total daily dose (μg) | Study duration | % of patients with pneumonia | |
|---|---|---|---|---|
ICS/LABA | LABA | |||
Calverley et al.12 | FP/S 1000/100 versus S 100 | 3 years | 19.6 | 13.3 |
Kardos et al.45 | FP/S 1000/100 versus S 100 | 44 weeks | 4.5 | 1.4 |
Calverley et al.3 | BUD/FF 640/18 versus FF 18 | 12 months | 3.1 | 2.7 |
Ferguson et al.4 | FP/S 500/100 versus S 100 | 12 months | 7.0 | 4.0 |
Rennard et al.7 | BUD/FF 320/9 versus FF 9 | 12 months | 3.0 | 3.4 |
Rennard et al.7 | BUD/FF 160/9 versus FF 9 | 12 months | 3.0 | 3.4 |
Anzueto et al.46 | FP/S 500/100 versus S 100 | 52 weeks | 6.6 | 2.5 |
Carlverley et al.20 | BDP/FF 400/24 versus FF 24 | 48 weeks | 2.1 | 0.4 |
Carlverley et al.20 | BUD/FF 800/24 versus FF 24 | 48 weeks | 2.9 | 0.4 |
Sharafkhaneh et al.44 | BUD/FF 320/9 versus FF 9 | 12 months | 6.4 | 2.7 |
Sharafkhaneh et al.44 | BUD/FF 160/9 versus FF 9 | 12 months | 4.7 | 2.7 |
Dransfield et al.6 | FF/Vil 100/25 versus Vil 25 | 52 weeks | 6.3 | 3.3 |
Wedzicha et al.28 | BDP/FF 400/24 versus FF 24 | 48 weeks | 3.8 | 1.8 |
